Stem Cell Therapy International Corp. (SCTI), Tampa, FL, develops, manufactures, and distributes stem cell xeno-transplants (of animal origin) for medical treatment. SCTI is the world’s largest manufacturer of precursor stem cell xeno-transplants, which have been used to treat a wide range of conditions including: complications of diabetes, aging disease, neurological disorders, genetic diseases and immune deficiency disorders. Its method of preparing precursor stem cell xeno-transplants is US patent pending. Its stem cell xeno-transplants can be implanted with "state-of-the-art" safety and without requiring immunosuppression to prevent rejection of stem cells. SCTI has become the leader of the stem cell xeno-transplantation field, since
1. by our unique patented (U.S. Patent pending) technology of tissue culture we had overcome the problem of adverse immunological reactions toward SCT’s, whereby their therapeutic use does not require immunosuppression,
2. we lowered the risk of transfer of xeno-zoonoses (infections transferred from animals to humans) down to zero by fulfilling all pertinent requirements of "PHS Guidelines on Infectious Disease Issues in Xenotransplantation" of January 19, 2001 (Federal Register, Volume 66, Number 19, pages 8120 – 1), issued initially as a "Draft" on September 23, 1996 (available from Federal Register under 61FR49920.
Stem Cell Therapy International Corp., (OTC: ATYD.PK), announced on Sept. 16, 2005, that it has been acquired by Altadyne, Inc., a Nevada corporation. Stem Cell Therapy International Corp. will trade under the symbol "ATYD.PK." On October 14, 2005 Stem Cell Therapy International, Inc. announced that it has changed its stock symbol to OTC BB: SCII.OB and will begin trading under the new stock symbol effective immediately.
USA - Florida
2203 North Lois Ave.
9th Floor
Tampa, FL 33607
E -mail: info@scticorp.com
Phone: 813.600.4088
Fax: 813.830.6112
